



ANNOUNCEMENT NO. 222

12 April 2022

Revenue and EBITDA guidance raised

In the third quarter of the financial year 2021/22, ChemoMetec continued its positive development, and sales and order intake developed significantly better than expected.

Based on the above, ChemoMetec now expects revenue in the financial year 2021/22 in the DKK 420-425 million range, up from DKK 385-395 million, and EBITDA is expected to be in the DKK 218-221 million range, up from DKK 195-200 million.

For further information

Steen Søndergaard, CEO, ChemoMetec A/S

Phone: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.